P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
a study on Breast Cancer Ovarian Cancer Lung Cancer Non-Small Cell Lung Cancer Colorectal Cancer Pancreatic Cancer Kidney Cancer Renal Cell Carcinoma Nasopharyngeal Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Stomach Cancer Solid Tumor
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer, Carcinoma, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Lead Scientist at UCSF
- David Oh
I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers. Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR).
- accepting new patients
- Start Date
- Completion Date
- Poseida Therapeutics, Inc.
- Phase 1 research study
- Study Type
- Expecting 100 study participants
- Last Updated